← Back to Home

Three-Year Follow-Up of Melanoma Vaccine EVX-01: Six Patients Maintain Responses During Extended Treatment

Six patients who previously received the vaccine and immunotherapy showed no tumor progression during a one-year extension on the vaccine alone. This small study offers signs of durable efficacy, but cannot yet distinguish the vaccine’s independent contribution.

By SURL BioNews

In treating advanced melanoma, how long disease control lasts after tumors shrink is equally important. On October 19, Evaxion announced follow-up results from its Phase 2 trial of the personalized cancer vaccine EVX-01: all six patients who entered the treatment extension maintained their existing treatment responses at the three-year follow-up, with no tumor progression observed. This is a preliminary signal of durable efficacy, but interpreting it requires a clear understanding of the scope of those six patients.

The original trial enrolled 16 patients with advanced melanoma, who received EVX-01 combined with the anti-PD-1 immunotherapy pembrolizumab for the first two years. Of the 12 patients who achieved an objective treatment response, six entered an additional one-year extension, during which they received only EVX-01. RTTNews’s report on the same announcement also explicitly limited the finding of no progression to these six patients who continued in the extension. It cannot be interpreted as showing that all participants remained free of progression for three years.

EVX-01 is a personalized peptide vaccine. Its artificial intelligence platform selects tumor-specific neoantigens based on each patient’s tumor and immune characteristics, which are then made into a vaccine intended to guide T cells to recognize cancer cells. AI’s specific role here is to help select targets for immune attack; whether those selected targets deliver clinical benefits still needs to be validated through patients’ immune response and disease follow-up data.

Earlier two-year results showed an objective response rate of 75% and a complete response rate of 25% among the 16 patients. An objective response means tumor shrinkage meets the assessment criteria, while a complete response means evaluable lesions have disappeared. Neither is equivalent to a cure. This update adds information about the subsequent disease course of some patients who had already responded, rather than providing a new efficacy rate for the entire group.

Immune testing offers another layer of evidence. According to the two-year data previously released by the company and relayed in Investing.com’s latest report, all patients developed immune responses, and 86% of the neoantigens included in the vaccine elicited specific T-cell responses. However, stimulating immune cells and extending life represent different levels of evidence; this percentage also cannot be treated as the proportion of patients who benefited.

The study’s most important limitations are its small sample, lack of a control group, and an extension that included only half of the patients who had already responded to treatment. This selection makes it difficult for the results to represent the broader population with advanced melanoma. Even though only the vaccine was used in the third year, a lasting effect from prior pembrolizumab treatment cannot be ruled out. These findings therefore cannot establish that EVX-01 alone maintained disease control or that it has been proven superior to existing treatments.

The company plans to present three-year clinical and immune data in poster 2006P at the European Society for Medical Oncology annual meeting on October 24, and to hold an online investigator briefing on October 29. Whether the full data clarify the remaining patients’ subsequent disease course, the eligibility criteria for the extension, and safety will affect how persuasive these six cases are. How much additional efficacy the vaccine provides still needs to be answered by larger studies with a controlled design.

References

  1. Evaxion via GlobeNewswire / Ritzau
  2. Evaxion via GlobeNewswire
  3. RTTNews
  4. Investing.com